{"created":"2023-05-15T14:59:26.840792+00:00","id":80656,"links":{},"metadata":{"_buckets":{"deposit":"e258b9aa-335e-43b6-a31f-3fdb0456fc99"},"_deposit":{"created_by":1,"id":"80656","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"80656"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00080656","sets":["10:28"]},"author_link":["891414","891420","891421","891423","891413","891416","891422","891419","891418","891412","891415","891417"],"item_10005_date_7":{"attribute_name":"発表年月日","attribute_value_mlt":[{"subitem_date_issued_datetime":"2020-10-01","subitem_date_issued_type":"Issued"}]},"item_10005_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Podoplanin (PDPN) is a glycoprotein that is highly expressed in malignant mesothelioma. We previously showed an anti-PDPN antibody NZ-12 has the potential as a new therapeutic agent for malignant mesothelioma. Here, we developed a novel anti-PDPN antibody NZ-16 having a different constant region from NZ-12. The in vitro and in vivo properties of radiolabeled NZ-16 and the antitumor effects were evaluated in mesothelioma and glioblastoma xenograft mouse models. In vitro assays showed radiolabeled NZ-16 has a higher affinity to PDPN-expressing cells H226 mesothelioma cells and LN319 glioblastoma cells than radiolabeled NZ-12. In vivo biodistribution studies showed high uptake of radiolabeled NZ-16 in H226 and LN319 tumors. Radioimmunotherapy (RIT) with radiolabeled NZ-16 significantly suppressed tumor volumes without obvious adverse events such as body weight loss in both models. The antitumor efficacy of radiolabeled NZ-16 was higher than that of NZ-12. Our findings suggest that RIT with radiolabeled NZ-16 has the potential as a superior therapeutic option for PDPN-expressing tumors.","subitem_description_type":"Abstract"}]},"item_10005_description_6":{"attribute_name":"会議概要（会議名, 開催地, 会期, 主催者等）","attribute_value_mlt":[{"subitem_description":"第79回日本癌学会学術総会","subitem_description_type":"Other"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Sudo, Hitomi"}],"nameIdentifiers":[{"nameIdentifier":"891412","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tsuji, Atsushi"}],"nameIdentifiers":[{"nameIdentifier":"891413","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Sugyo, Aya"}],"nameIdentifiers":[{"nameIdentifier":"891414","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Fujiwara, Kentaro"}],"nameIdentifiers":[{"nameIdentifier":"891415","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Mika Kaneko"}],"nameIdentifiers":[{"nameIdentifier":"891416","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yukinari Kato"}],"nameIdentifiers":[{"nameIdentifier":"891417","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Higashi, Tatsuya"}],"nameIdentifiers":[{"nameIdentifier":"891418","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Sudo, Hitomi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"891419","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tsuji, Atsushi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"891420","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Sugyo, Aya","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"891421","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Fujiwara, Kentaro","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"891422","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Higashi, Tatsuya","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"891423","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"conference object","resourceuri":"http://purl.org/coar/resource_type/c_c94f"}]},"item_title":"A novel anti-podoplanin antibody NZ-16 has the potential as a radioimmunotherapy agent for solid tumors","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"A novel anti-podoplanin antibody NZ-16 has the potential as a radioimmunotherapy agent for solid tumors"}]},"item_type_id":"10005","owner":"1","path":["28"],"pubdate":{"attribute_name":"公開日","attribute_value":"2020-09-17"},"publish_date":"2020-09-17","publish_status":"0","recid":"80656","relation_version_is_last":true,"title":["A novel anti-podoplanin antibody NZ-16 has the potential as a radioimmunotherapy agent for solid tumors"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T21:28:37.135751+00:00"}